Ticagrelor

CHICAGO — Bentracimab, a recombinant human immunoglobulin G1 monoclonal antibody fragment, restored platelet function in patients on ticagrelor undergoing urgent surgery or with major bleeding, according to data from the REVERSE-IT trial.

Since the advent of drug-eluting stents, there has been a debate in the intervention community over how long dual antiplatelet therapy should last after PCI.

ATLANTA — In patients with ACS who underwent PCI, ticagrelor monotherapy after 1 month lowered bleeding risk by 55% compared with dual antiplatelet therapy for 12 months, according to the results of the ULTIMATE-DAPT trial.

SAN FRANCISCO — In a new meta-analysis, researchers reaffirmed safety and efficacy of ticagrelor monotherapy to reduce major bleeding after 3-month dual antiplatelet therapy among patients who underwent PCI for ACS.

SAN FRANCISCO — In patients with ACS, stopping aspirin for ticagrelor monotherapy within 1 month of receiving a drug-eluting stent did not increase adverse CV and bleeding events compared with 12 months of dual antiplatelet therapy.

Ticagrelor monotherapy after 3-month dual antiplatelet therapy was not associated with greater risk for repeat revascularization or MACCE at 1 year after PCI vs. continued DAPT, a speaker reported.

CHICAGO — Cangrelor infusion in adults with CAD pretreated with ticagrelor was associated with enhanced platelet inhibition compared with placebo, with no observed drug-drug interactions in the cangrelor group, researchers reported.

After a minor stroke or transient ischemic attack, patients with normal vs. impaired renal function treated with ticagrelor plus aspirin had lower risk for stroke at 90 days compared with clopidogrel plus aspirin, researchers reported.

For adults who undergo PCI with a drug-eluting stent, recommendations for dual antiplatelet therapy have evolved from a standard 1-year duration for most patients to a more nuanced approach that balances risks for ischemia and bleeding.

Among patients with CAD, P2Y12 monotherapy was superior to aspirin monotherapy for prevention of CV death, MI and stroke, according to an individual patient data meta-analysis presented at the European Society of Cardiology Congress.